Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 444

1.

Oncogenic KRAS Reduces Expression of FGF21 in Acinar Cells to Promote Pancreatic Tumorigenesis in Mice on a High-Fat Diet.

Luo Y, Yang Y, Liu M, Wang D, Wang F, Bi Y, Ji J, Li S, Liu Y, Chen R, Huang H, Wang X, Swidnicka-Siergiejko AK, Janowitz T, Beyaz S, Wang G, Xu S, Bialkowska AB, Luo CK, Pin CL, Liang G, Lu X, Wu M, Shroyer KR, Wolff RA, Plunkett W, Ji B, Li Z, Li E, Li X, Yang VW, Logsdon CD, Abbruzzese JL, Lu W.

Gastroenterology. 2019 Jul 25. pii: S0016-5085(19)41127-X. doi: 10.1053/j.gastro.2019.07.030. [Epub ahead of print]

PMID:
31352001
2.

Genetic variants in the liver kinase B1-AMP-activated protein kinase pathway genes and pancreatic cancer risk.

Xu X, Qian D, Liu H, Cruz D, Luo S, Walsh KM, Abbruzzese JL, Zhang X, Wei Q.

Mol Carcinog. 2019 Aug;58(8):1338-1348. doi: 10.1002/mc.23018. Epub 2019 Apr 17.

PMID:
30997723
3.

Three novel genetic variants in NRF2 signaling pathway genes are associated with pancreatic cancer risk.

Yang W, Liu H, Duan B, Xu X, Carmody D, Luo S, Walsh KM, Abbruzzese JL, Zhang X, Chen X, Wei Q.

Cancer Sci. 2019 Jun;110(6):2022-2032. doi: 10.1111/cas.14017. Epub 2019 May 6.

4.

Obesogenic high-fat diet heightens aerobic glycolysis through hyperactivation of oncogenic KRAS.

Wang D, Bi Y, Hu L, Luo Y, Ji J, Mao AZ, Logsdon CD, Li E, Abbruzzese JL, Li Z, Yang VW, Lu W.

Cell Commun Signal. 2019 Feb 28;17(1):19. doi: 10.1186/s12964-019-0333-7.

5.

Measurement of Reactive Oxygen Species by Fluorescent Probes in Pancreatic Cancer Cells.

Luo Y, Wang D, Abbruzzese JL, Lu W.

Methods Mol Biol. 2019;1882:207-219. doi: 10.1007/978-1-4939-8879-2_19.

PMID:
30378057
6.

The Interface of Pancreatic Cancer With Diabetes, Obesity, and Inflammation: Research Gaps and Opportunities: Summary of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop.

Abbruzzese JL, Andersen DK, Borrebaeck CAK, Chari ST, Costello E, Cruz-Monserrate Z, Eibl G, Engleman EG, Fisher WE, Habtezion A, Kim SK, Korc M, Logsdon C, Lyssiotis CA, Pandol SJ, Rustgi A, Wolfe BM, Zheng L, Powers AC.

Pancreas. 2018 May/Jun;47(5):516-525. doi: 10.1097/MPA.0000000000001037.

7.

An Intergroup Randomized Phase II Study of Bevacizumab or Cetuximab in Combination with Gemcitabine and in Combination with Chemoradiation in Patients with Resected Pancreatic Carcinoma: A Trial of the ECOG-ACRIN Cancer Research Group (E2204).

Berlin JD, Feng Y, Catalano P, Abbruzzese JL, Philip PA, McWilliams RR, Lowy AM, Benson AB III, Blackstock AW.

Oncology. 2018;94(1):39-46. doi: 10.1159/000480295. Epub 2017 Oct 18.

8.

Diabetes, Pancreatogenic Diabetes, and Pancreatic Cancer.

Andersen DK, Korc M, Petersen GM, Eibl G, Li D, Rickels MR, Chari ST, Abbruzzese JL.

Diabetes. 2017 May;66(5):1103-1110. doi: 10.2337/db16-1477.

9.

Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer.

Capello M, Bantis LE, Scelo G, Zhao Y, Li P, Dhillon DS, Patel NJ, Kundnani DL, Wang H, Abbruzzese JL, Maitra A, Tempero MA, Brand R, Firpo MA, Mulvihill SJ, Katz MH, Brennan P, Feng Z, Taguchi A, Hanash SM.

J Natl Cancer Inst. 2017 Apr 1;109(4). doi: 10.1093/jnci/djw266.

10.

Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience.

Cloyd JM, Katz MH, Prakash L, Varadhachary GR, Wolff RA, Shroff RT, Javle M, Fogelman D, Overman M, Crane CH, Koay EJ, Das P, Krishnan S, Minsky BD, Lee JH, Bhutani MS, Weston B, Ross W, Bhosale P, Tamm EP, Wang H, Maitra A, Kim MP, Aloia TA, Vauthey JN, Fleming JB, Abbruzzese JL, Pisters PW, Evans DB, Lee JE.

J Gastrointest Surg. 2017 Jan;21(1):164-174. doi: 10.1007/s11605-016-3265-1. Epub 2016 Oct 24.

PMID:
27778257
11.

FGF21-FGFR1 Coordinates Phospholipid Homeostasis, Lipid Droplet Function, and ER Stress in Obesity.

Ye M, Lu W, Wang X, Wang C, Abbruzzese JL, Liang G, Li X, Luo Y.

Endocrinology. 2016 Dec;157(12):4754-4769. Epub 2016 Oct 3.

PMID:
27690692
12.

Development of a Novel c-MET-Based CTC Detection Platform.

Zhang T, Boominathan R, Foulk B, Rao C, Kemeny G, Strickler JH, Abbruzzese JL, Harrison MR, Hsu DS, Healy P, Li J, Pi C, Prendergast KM, Hobbs C, Gemberling S, George DJ, Hurwitz HI, Connelly M, Garcia-Blanco MA, Armstrong AJ.

Mol Cancer Res. 2016 Jun;14(6):539-47. doi: 10.1158/1541-7786.MCR-16-0011. Epub 2016 Mar 7.

13.

Clinical Insights Into the Biology and Treatment of Pancreatic Cancer.

Mettu NB, Abbruzzese JL.

J Oncol Pract. 2016 Jan;12(1):17-23. doi: 10.1200/JOP.2015.009092. Review.

PMID:
26759461
14.

RECQ1 A159C Polymorphism Is Associated With Overall Survival of Patients With Resected Pancreatic Cancer: A Replication Study in NRG Oncology Radiation Therapy Oncology Group 9704.

Li D, Moughan J, Crane C, Hoffman JP, Regine WF, Abrams RA, Safran H, Liu C, Chang P, Freedman GM, Winter KA, Guha C, Abbruzzese JL.

Int J Radiat Oncol Biol Phys. 2016 Mar 1;94(3):554-60. doi: 10.1016/j.ijrobp.2015.10.062. Epub 2015 Nov 5.

15.

Impacts of new-onset and long-term diabetes on clinical outcome of pancreatic cancer.

Li D, Mao Y, Chang P, Liu C, Hassan MM, Yeung SJ, Abbruzzese JL.

Am J Cancer Res. 2015 Sep 15;5(10):3260-9. eCollection 2015.

16.

ABO non-O type as a risk factor for thrombosis in patients with pancreatic cancer.

Li D, Pise MN, Overman MJ, Liu C, Tang H, Vadhan-Raj S, Abbruzzese JL.

Cancer Med. 2015 Nov;4(11):1651-8. doi: 10.1002/cam4.513. Epub 2015 Aug 15.

17.

Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma.

Fogelman D, Sugar EA, Oliver G, Shah N, Klein A, Alewine C, Wang H, Javle M, Shroff R, Wolff RA, Abbruzzese JL, Laheru D, Diaz LA Jr.

Cancer Chemother Pharmacol. 2015 Sep;76(3):489-498. doi: 10.1007/s00280-015-2788-6. Epub 2015 Jul 1.

18.

Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer.

Reddy SM, Kopetz S, Morris J, Parikh N, Qiao W, Overman MJ, Fogelman D, Shureiqi I, Jacobs C, Malik Z, Jimenez CA, Wolff RA, Abbruzzese JL, Gallick G, Eng C.

Invest New Drugs. 2015 Aug;33(4):977-84. doi: 10.1007/s10637-015-0257-z. Epub 2015 Jun 12.

PMID:
26062928
19.

Intra-tumoral heterogeneity of gemcitabine delivery and mass transport in human pancreatic cancer.

Koay EJ, Baio FE, Ondari A, Truty MJ, Cristini V, Thomas RM, Chen R, Chatterjee D, Kang Y, Zhang J, Court L, Bhosale PR, Tamm EP, Qayyum A, Crane CH, Javle M, Katz MH, Gottumukkala VN, Rozner MA, Shen H, Lee JE, Wang H, Chen Y, Plunkett W, Abbruzzese JL, Wolff RA, Maitra A, Ferrari M, Varadhachary GR, Fleming JB.

Phys Biol. 2014 Nov 26;11(6):065002. doi: 10.1088/1478-3975/11/6/065002.

20.

New option for the initial management of metastatic pancreatic cancer?

Abbruzzese JL, Hess KR.

J Clin Oncol. 2014 Aug 10;32(23):2405-7. doi: 10.1200/JCO.2013.54.4155. Epub 2014 Jun 30. No abstract available.

21.

Development and validation of insulin-like growth factor-1 score to assess hepatic reserve in hepatocellular carcinoma.

Kaseb AO, Xiao L, Hassan MM, Chae YK, Lee JS, Vauthey JN, Krishnan S, Cheung S, Hassabo HM, Aloia T, Conrad C, Curley SA, Vierling JM, Jalal P, Raghav K, Wallace M, Rashid A, Abbruzzese JL, Wolff RA, Morris JS.

J Natl Cancer Inst. 2014 May 9;106(5). pii: dju088. doi: 10.1093/jnci/dju088.

22.

Aberrant expression of p53, p21, cyclin D1, and Bcl2 and their clinicopathological correlation in ampullary adenocarcinoma.

Guo R, Overman M, Chatterjee D, Rashid A, Shroff S, Wang H, Katz MH, Fleming JB, Varadhachary GR, Abbruzzese JL, Wang H.

Hum Pathol. 2014 May;45(5):1015-23. doi: 10.1016/j.humpath.2013.12.016. Epub 2014 Jan 17.

PMID:
24746206
23.

Transport properties of pancreatic cancer describe gemcitabine delivery and response.

Koay EJ, Truty MJ, Cristini V, Thomas RM, Chen R, Chatterjee D, Kang Y, Bhosale PR, Tamm EP, Crane CH, Javle M, Katz MH, Gottumukkala VN, Rozner MA, Shen H, Lee JE, Wang H, Chen Y, Plunkett W, Abbruzzese JL, Wolff RA, Varadhachary GR, Ferrari M, Fleming JB.

J Clin Invest. 2014 Apr;124(4):1525-36. doi: 10.1172/JCI73455. Epub 2014 Mar 10.

24.

Evaluating physician performance in oncology: moneyball becomes impactball.

Fisch MJ, Abbruzzese JL, Hong WK.

J Oncol Pract. 2014 Jan;10(1):79-81. doi: 10.1200/JOP.2013.001218. No abstract available.

PMID:
24443736
25.

Solid pseudopapillary neoplasm of the pancreas: clinicopathologic and survival analyses of 64 cases from a single institution.

Estrella JS, Li L, Rashid A, Wang H, Katz MH, Fleming JB, Abbruzzese JL, Wang H.

Am J Surg Pathol. 2014 Feb;38(2):147-57. doi: 10.1097/PAS.0000000000000141.

PMID:
24418850
26.

SOX9: a useful marker for pancreatic ductal lineage of pancreatic neoplasms.

Shroff S, Rashid A, Wang H, Katz MH, Abbruzzese JL, Fleming JB, Wang H.

Hum Pathol. 2014 Mar;45(3):456-63. doi: 10.1016/j.humpath.2013.10.008. Epub 2013 Oct 19.

27.

Reassessing hepatocellular carcinoma staging in a changing patient population.

Kaseb AO, Shah NN, Hassabo HM, Morris JS, Xiao L, Abaza YM, Soliman K, Lee JS, Vauthey JN, Wallace M, Aloia TA, Curley S, Abbruzzese JL, Hassan MM.

Oncology. 2014;86(2):63-71. doi: 10.1159/000356573. Epub 2014 Jan 8.

28.

The CUL7/F-box and WD repeat domain containing 8 (CUL7/Fbxw8) ubiquitin ligase promotes degradation of hematopoietic progenitor kinase 1.

Wang H, Chen Y, Lin P, Li L, Zhou G, Liu G, Logsdon C, Jin J, Abbruzzese JL, Tan TH, Wang H.

J Biol Chem. 2014 Feb 14;289(7):4009-17. doi: 10.1074/jbc.M113.520106. Epub 2013 Dec 20.

29.

Deficiency of metabolic regulator FGFR4 delays breast cancer progression through systemic and microenvironmental metabolic alterations.

Luo Y, Yang C, Ye M, Jin C, Abbruzzese JL, Lee MH, Yeung SC, McKeehan WL.

Cancer Metab. 2013 Nov 25;1(1):21. doi: 10.1186/2049-3002-1-21.

30.

Treatment sequencing for resectable pancreatic cancer: influence of early metastases and surgical complications on multimodality therapy completion and survival.

Tzeng CW, Tran Cao HS, Lee JE, Pisters PW, Varadhachary GR, Wolff RA, Abbruzzese JL, Crane CH, Evans DB, Wang H, Abbott DE, Vauthey JN, Aloia TA, Fleming JB, Katz MH.

J Gastrointest Surg. 2014 Jan;18(1):16-24; discussion 24-5. doi: 10.1007/s11605-013-2412-1. Epub 2013 Nov 16.

PMID:
24241967
31.

The expression of PTEN is associated with improved prognosis in patients with ampullary adenocarcinoma after pancreaticoduodenectomy.

Shroff S, Overman MJ, Rashid A, Shroff RT, Wang H, Chatterjee D, Katz MH, Lee JE, Wolff RA, Abbruzzese JL, Fleming JB, Wang H.

Arch Pathol Lab Med. 2013 Nov;137(11):1619-26. doi: 10.5858/arpa.2012-0418-OA.

32.

Clinicopathologic features and prognosis of duodenal adenocarcinoma and comparison with ampullary and pancreatic ductal adenocarcinoma.

Zenali M, Overman MJ, Rashid A, Broaddus RB, Wang H, Katz MH, Fleming JB, Abbruzzese JL, Wang H.

Hum Pathol. 2013 Dec;44(12):2792-8. doi: 10.1016/j.humpath.2013.07.030. Epub 2013 Oct 15.

33.

Morbidity and mortality after pancreaticoduodenectomy in patients with borderline resectable type C clinical classification.

Tzeng CW, Katz MH, Fleming JB, Lee JE, Pisters PW, Holmes HM, Varadhachary GR, Wolff RA, Abbruzzese JL, Vauthey JN, Aloia TA.

J Gastrointest Surg. 2014 Jan;18(1):146-55; discussion 155-6. doi: 10.1007/s11605-013-2371-6. Epub 2013 Oct 16.

PMID:
24129825
34.

Pancreatic intraepithelial neoplasia and histological changes in non-neoplastic pancreas associated with neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma.

Chatterjee D, Katz MH, Rashid A, Estrella JS, Wang H, Varadhachary GR, Wolff RA, Lee JE, Pisters PW, Abbruzzese JL, Fleming JB, Wang H.

Histopathology. 2013 Dec;63(6):841-51. doi: 10.1111/his.12234. Epub 2013 Sep 20.

35.

Prognostic indicators and treatment outcome in 94 cases of fibrolamellar hepatocellular carcinoma.

Kaseb AO, Shama M, Sahin IH, Nooka A, Hassabo HM, Vauthey JN, Aloia T, Abbruzzese JL, Subbiah IM, Janku F, Curley S, Hassan MM.

Oncology. 2013;85(4):197-203. doi: 10.1159/000354698. Epub 2013 Sep 19.

36.

Modified cisplatin/interferon α-2b/doxorubicin/5-fluorouracil (PIAF) chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate, resectability, and survival of initially unresectable hepatocellular carcinoma.

Kaseb AO, Shindoh J, Patt YZ, Roses RE, Zimmitti G, Lozano RD, Hassan MM, Hassabo HM, Curley SA, Aloia TA, Abbruzzese JL, Vauthey JN.

Cancer. 2013 Sep 15;119(18):3334-42. doi: 10.1002/cncr.28209. Epub 2013 Jul 2.

37.

Gene expression profiling of ampullary carcinomas classifies ampullary carcinomas into biliary-like and intestinal-like subtypes that are prognostic of outcome.

Overman MJ, Zhang J, Kopetz S, Davies M, Jiang ZQ, Stemke-Hale K, Rümmele P, Pilarsky C, Grützmann R, Hamilton S, Hwang R, Abbruzzese JL, Varadhachary G, Broom B, Wang H.

PLoS One. 2013 Jun 11;8(6):e65144. doi: 10.1371/journal.pone.0065144. Print 2013. Erratum in: PLoS One. 2013;8(7). doi:10.1371/annotation/6afdd046-e1a7-4421-b7ec-0c9492ce2544. Zhi-Qin, Jiang [corrected to Jiang, Zhi-Qin].

38.

Genetic variation in the PNPLA3 gene and hepatocellular carcinoma in USA: risk and prognosis prediction.

Hassan MM, Kaseb A, Etzel CJ, El-Serag H, Spitz MR, Chang P, Hale KS, Liu M, Rashid A, Shama M, Abbruzzese JL, Loyer EM, Kaur H, Hassabo HM, Vauthey JN, Wray CJ, Hassan BS, Patt YZ, Hawk E, Soliman KM, Li D.

Mol Carcinog. 2013 Nov;52 Suppl 1:E139-47. doi: 10.1002/mc.22057. Epub 2013 Jun 15.

39.

Side pockets provide the basis for a new mechanism of Kv channel-specific inhibition.

Marzian S, Stansfeld PJ, Rapedius M, Rinné S, Nematian-Ardestani E, Abbruzzese JL, Steinmeyer K, Sansom MS, Sanguinetti MC, Baukrowitz T, Decher N.

Nat Chem Biol. 2013 Aug;9(8):507-13. doi: 10.1038/nchembio.1271. Epub 2013 Jun 2.

40.

The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancer.

Khalil MA, Qiao W, Carlson P, George B, Javle M, Overman M, Varadhachary G, Wolff RA, Abbruzzese JL, Fogelman DR.

Invest New Drugs. 2013 Oct;31(5):1375-83. doi: 10.1007/s10637-013-9967-2. Epub 2013 May 4.

PMID:
23645398
41.

Frequency and intensity of postoperative surveillance after curative treatment of pancreatic cancer: a cost-effectiveness analysis.

Tzeng CW, Abbott DE, Cantor SB, Fleming JB, Lee JE, Pisters PW, Varadhachary GR, Abbruzzese JL, Wolff RA, Ahmad SA, Katz MH.

Ann Surg Oncol. 2013 Jul;20(7):2197-203. doi: 10.1245/s10434-013-2889-6. Epub 2013 Feb 14.

PMID:
23408126
42.

The cost-effectiveness of neoadjuvant chemoradiation is superior to a surgery-first approach in the treatment of pancreatic head adenocarcinoma.

Abbott DE, Tzeng CW, Merkow RP, Cantor SB, Chang GJ, Katz MH, Bentrem DJ, Bilimoria KY, Crane CH, Varadhachary GR, Abbruzzese JL, Wolff RA, Lee JE, Evans DB, Fleming JB.

Ann Surg Oncol. 2013 Dec;20 Suppl 3:S500-8. doi: 10.1245/s10434-013-2882-0. Epub 2013 Feb 10.

PMID:
23397153
43.

Association of diabetes and perineural invasion in pancreatic cancer.

Sahin IH, Shama MA, Tanaka M, Abbruzzese JL, Curley SA, Hassan M, Li D.

Cancer Med. 2012 Dec;1(3):357-62. doi: 10.1002/cam4.43. Epub 2012 Oct 30.

44.

Deciphering the mechanisms of tumorigenesis in human pancreatic ductal epithelial cells.

Chang Z, Li Z, Wang X, Kang Y, Yuan Y, Niu J, Wang H, Chatterjee D, Fleming JB, Li M, Abbruzzese JL, Chiao PJ.

Clin Cancer Res. 2013 Feb 1;19(3):549-59. doi: 10.1158/1078-0432.CCR-12-0032. Epub 2013 Jan 22.

45.

BSTA promotes mTORC2-mediated phosphorylation of Akt1 to suppress expression of FoxC2 and stimulate adipocyte differentiation.

Yao Y, Suraokar M, Darnay BG, Hollier BG, Shaiken TE, Asano T, Chen CH, Chang BH, Lu Y, Mills GB, Sarbassov D, Mani SA, Abbruzzese JL, Reddy SA.

Sci Signal. 2013 Jan 8;6(257):ra2. doi: 10.1126/scisignal.2003295.

46.

Loss of phosphatase and tensin homolog expression is associated with recurrence and poor prognosis in patients with pancreatic ductal adenocarcinoma.

Foo WC, Rashid A, Wang H, Katz MH, Lee JE, Pisters PW, Wolff RA, Abbruzzese JL, Fleming JB, Wang H.

Hum Pathol. 2013 Jun;44(6):1024-30. doi: 10.1016/j.humpath.2012.09.001. Epub 2012 Dec 20.

47.

Solid pseudopapillary neoplasm of the pancreas with prominent atypical multinucleated giant tumour cells.

Li L, Othman M, Rashid A, Wang H, Li Z, Katz MH, Lee JE, Pisters PW, Abbruzzese JL, Fleming JB, Wang H.

Histopathology. 2013 Feb;62(3):465-71. doi: 10.1111/his.12023. Epub 2012 Nov 8.

48.

Use of research biopsies in clinical trials: are risks and benefits adequately discussed?

Overman MJ, Modak J, Kopetz S, Murthy R, Yao JC, Hicks ME, Abbruzzese JL, Tam AL.

J Clin Oncol. 2013 Jan 1;31(1):17-22. doi: 10.1200/JCO.2012.43.1718. Epub 2012 Nov 5.

49.

Overexpression of protein phosphatase 4 correlates with poor prognosis in patients with stage II pancreatic ductal adenocarcinoma.

Weng S, Wang H, Chen W, Katz MH, Chatterjee D, Lee JE, Pisters PW, Gomez HF, Abbruzzese JL, Fleming JB, Wang H.

Cancer Epidemiol Biomarkers Prev. 2012 Aug;21(8):1336-43. doi: 10.1158/1055-9965.EPI-12-0223. Epub 2012 Jun 4.

50.

Multimodality therapy offers a chance for cure in patients with pancreatic adenocarcinoma deemed unresectable at first operative exploration.

Truty MJ, Thomas RM, Katz MH, Vauthey JN, Crane C, Varadhachary GR, Wolff RA, Abbruzzese JL, Lee JE, Fleming JB.

J Am Coll Surg. 2012 Jul;215(1):41-51; discussion 51-2. doi: 10.1016/j.jamcollsurg.2012.03.024. Epub 2012 May 18.

Supplemental Content

Loading ...
Support Center